GRITSTONE ONCOLOGY INC's ticker is GRTS and the CUSIP is 39868T105. A total of 67 filers reported holding GRITSTONE ONCOLOGY INC in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $263,150 | -34.0% | 153,100 | -25.1% | 0.00% | – |
| Q2 2023 | $398,723 | -55.8% | 204,468 | -37.0% | 0.00% | – |
| Q1 2023 | $901,440 | +78422.6% | 324,337 | -2.6% | 0.00% | – |
| Q4 2022 | $1,148 | -99.8% | 332,927 | +24.0% | 0.00% | – |
| Q3 2022 | $690,000 | +78.3% | 268,413 | +68.0% | 0.00% | – |
| Q2 2022 | $387,000 | -47.8% | 159,800 | -11.1% | 0.00% | – |
| Q1 2022 | $741,000 | -74.4% | 179,802 | -20.1% | 0.00% | -100.0% |
| Q4 2021 | $2,894,000 | +50.3% | 225,003 | +26.3% | 0.00% | 0.0% |
| Q3 2021 | $1,925,000 | -3.6% | 178,216 | -18.5% | 0.00% | 0.0% |
| Q2 2021 | $1,997,000 | +279.7% | 218,708 | +291.4% | 0.00% | – |
| Q1 2021 | $526,000 | +108.7% | 55,872 | -12.6% | 0.00% | – |
| Q4 2020 | $252,000 | +49.1% | 63,895 | +0.0% | 0.00% | – |
| Q3 2020 | $169,000 | -54.9% | 63,887 | +13.1% | 0.00% | – |
| Q2 2020 | $375,000 | +125.9% | 56,498 | +98.0% | 0.00% | – |
| Q1 2020 | $166,000 | – | 28,539 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 3,561,150 | $9,152,000 | 15.60% |
| Frazier Life Sciences Management, L.P. | 5,237,348 | $13,460,000 | 1.04% |
| Redmile Group, LLC | 6,952,760 | $17,869,000 | 0.69% |
| Palo Alto Investors LP | 2,330,504 | $5,989,000 | 0.47% |
| ACT CAPITAL MANAGEMENT, LLC | 47,500 | $122,000 | 0.17% |
| SkyOak Wealth, LLC | 132,851 | $341,000 | 0.12% |
| Artal Group S.A. | 750,000 | $1,928,000 | 0.08% |
| CORNERCAP INVESTMENT COUNSEL INC | 77,046 | $198,000 | 0.04% |
| CAXTON ASSOCIATES LP | 95,190 | $245,000 | 0.03% |
| XTX Topco Ltd | 50,517 | $130,000 | 0.03% |